Regeneron Pharmaceuticals Stock Analysis
REGN Stock | USD 738.00 6.50 0.87% |
Regeneron Pharmaceuticals is fairly valued with Real Value of 733.01 and Target Price of 912.52. The main objective of Regeneron Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Regeneron Pharmaceuticals is worth, separate from its market price. There are two main types of Regeneron Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Regeneron Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Regeneron Pharmaceuticals is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Regeneron Stock trading window is adjusted to America/New York timezone.
Regeneron |
Regeneron Stock Analysis Notes
About 91.0% of the company shares are owned by institutional investors. The book value of Regeneron Pharmaceuticals was at this time reported as 272.04. The company has Price/Earnings To Growth (PEG) ratio of 1.1. Regeneron Pharmaceuticals recorded earning per share (EPS) of 40.44. The entity had not issued any dividends in recent years. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10915 people. To find out more about Regeneron Pharmaceuticals contact the company at 914 847 7000 or learn more at https://www.regeneron.com.Regeneron Pharmaceuticals Quarterly Total Revenue |
|
Regeneron Pharmaceuticals Investment Alerts
Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
Over 91.0% of the company shares are owned by institutional investors | |
Latest headline from businesswire.com: BioFuture 2024 Wraps Up Hundreds of High-Profile Attendees Joined Record Numbers of Investors and Media |
Regeneron Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Regeneron Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
2nd of February 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
2nd of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Regeneron Largest EPS Surprises
Earnings surprises can significantly impact Regeneron Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2004-07-26 | 2004-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
1999-10-28 | 1999-09-30 | -0.2 | -0.16 | 0.04 | 20 | ||
2008-11-04 | 2008-09-30 | -0.32 | -0.27 | 0.05 | 15 |
Regeneron Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Regeneron Pharmaceuticals' ESG score is a quantitative measure that evaluates Regeneron Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Regeneron Pharmaceuticals' operations that may have significant financial implications and affect Regeneron Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Regeneron Pharmaceuticals Thematic Classifications
In addition to having Regeneron Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
BiotechBiotechnology and pharmaceuticals production and services | ||
Cancer FightersPublic companies from health care and pharmaceutical sectors that are focused on fighting cancer |
Regeneron Stock Institutional Investors
Shares | Loomis, Sayles & Company Lp | 2024-06-30 | 1.2 M | Norges Bank | 2024-06-30 | 1.1 M | Amundi | 2024-06-30 | 1.1 M | Wellington Management Company Llp | 2024-06-30 | 1.1 M | Legal & General Group Plc | 2024-06-30 | 978.1 K | Bank Of America Corp | 2024-06-30 | 968.1 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 932.9 K | Northern Trust Corp | 2024-09-30 | 918.6 K | Amvescap Plc. | 2024-06-30 | 916.4 K | Fmr Inc | 2024-09-30 | 10.4 M | Vanguard Group Inc | 2024-09-30 | 9.3 M |
Regeneron Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 81.1 B.Regeneron Profitablity
The company has Profit Margin (PM) of 0.34 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.33 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.33.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.12 | 0.13 | |
Return On Capital Employed | 0.14 | 0.14 | |
Return On Assets | 0.12 | 0.13 | |
Return On Equity | 0.15 | 0.16 |
Management Efficiency
Regeneron Pharmaceuticals has return on total asset (ROA) of 0.0741 % which means that it generated a profit of $0.0741 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1717 %, meaning that it created $0.1717 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.13, while Other Current Assets are likely to drop about 197.8 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 243.42 | 255.59 | |
Tangible Book Value Per Share | 233.69 | 245.37 | |
Enterprise Value Over EBITDA | 20.13 | 21.14 | |
Price Book Value Ratio | 3.61 | 5.22 | |
Enterprise Value Multiple | 20.13 | 21.14 | |
Price Fair Value | 3.61 | 5.22 | |
Enterprise Value | 38.4 B | 40.3 B |
At Regeneron Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Operating Margin 0.3343 | Profit Margin 0.3361 | Beta 0.142 | Return On Assets 0.0741 | Return On Equity 0.1717 |
Technical Drivers
As of the 25th of November, Regeneron Pharmaceuticals holds the Coefficient Of Variation of (239.61), variance of 2.84, and Risk Adjusted Performance of (0.31). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regeneron Pharmaceuticals, as well as the relationship between them.Regeneron Pharmaceuticals Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Regeneron Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Regeneron Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Regeneron Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regeneron Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regeneron Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regeneron Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Andrew Murphy over six months ago Disposition of tradable shares by Andrew Murphy of Regeneron Pharmaceuticals at 962.87 subject to Rule 16b-3 | ||
Arthur Ryan over six months ago Disposition of tradable shares by Arthur Ryan of Regeneron Pharmaceuticals at 986.58 subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1706 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1706 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 |
Regeneron Pharmaceuticals Outstanding Bonds
Regeneron Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regeneron Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regeneron bonds can be classified according to their maturity, which is the date when Regeneron Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
REGENERON PHARMACEUTICALS INC Corp BondUS75886FAF45 | View | |
REGENERON PHARMACEUTICALS INC Corp BondUS75886FAE79 | View | |
US75884RBA05 Corp BondUS75884RBA05 | View | |
REGENCY CTRS L Corp BondUS75884RAV50 | View | |
US75884RAW34 Corp BondUS75884RAW34 | View | |
REGENCY CTRS L Corp BondUS75884RAU77 | View | |
US75884RAZ64 Corp BondUS75884RAZ64 | View |
Regeneron Pharmaceuticals Predictive Daily Indicators
Regeneron Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Regeneron Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 0.0183 | |||
Daily Balance Of Power | (0.47) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 744.52 | |||
Day Typical Price | 742.34 | |||
Market Facilitation Index | 13.77 | |||
Price Action Indicator | (9.76) | |||
Period Momentum Indicator | (6.50) | |||
Relative Strength Index | 15.57 |
Regeneron Pharmaceuticals Corporate Filings
F4 | 12th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 7th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 29th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 19th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Regeneron Pharmaceuticals Forecast Models
Regeneron Pharmaceuticals' time-series forecasting models are one of many Regeneron Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Regeneron Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Regeneron Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Regeneron Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Regeneron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Regeneron Pharmaceuticals. By using and applying Regeneron Stock analysis, traders can create a robust methodology for identifying Regeneron entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.32 | 0.34 | |
Operating Profit Margin | 0.31 | 0.32 | |
Net Profit Margin | 0.30 | 0.32 | |
Gross Profit Margin | 0.86 | 0.64 |
Current Regeneron Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Regeneron analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Regeneron analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
912.52 | Strong Buy | 26 | Odds |
Most Regeneron analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Regeneron stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Regeneron Pharmaceuticals, talking to its executives and customers, or listening to Regeneron conference calls.
Regeneron Stock Analysis Indicators
Regeneron Pharmaceuticals stock analysis indicators help investors evaluate how Regeneron Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Regeneron Pharmaceuticals shares will generate the highest return on investment. By understating and applying Regeneron Pharmaceuticals stock analysis, traders can identify Regeneron Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 3.1 B | |
Long Term Debt | 2 B | |
Common Stock Shares Outstanding | 113.7 M | |
Total Stockholder Equity | 26 B | |
Tax Provision | 385.3 M | |
Quarterly Earnings Growth Y O Y | 0.298 | |
Property Plant And Equipment Net | 4.1 B | |
Cash And Short Term Investments | 10.8 B | |
Cash | 2.7 B | |
Accounts Payable | 606.6 M | |
Net Debt | -27.1 M | |
50 Day M A | 945.0514 | |
Total Current Liabilities | 3.4 B | |
Other Operating Expenses | 8 B | |
Non Current Assets Total | 13.6 B | |
Forward Price Earnings | 16.3666 | |
Non Currrent Assets Other | 444.1 M | |
Stock Based Compensation | 885 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.44 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.